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Conclusions: The presented analytical dose calculation algorithm is 
applicable for any type of heterogeneity. The high calculation speed 
of the algorithm makes it feasible for use in clinical real time- 
treatment planning and thus for improving treatment quality. 
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Purpose/Objective: To evaluate and compare the dosimetric 
parameters of intraoperative treatment plans in prostate seed 
implants performed with loose seed and stranded seed techniques.  
Materials and Methods: Permanent prostate brachytherapy with I-125 
seeds as a monotherapy for patients with low and intermediate risk 
prostate cancer was implemented at our institute in 2009, and since 
then 147 patients have been treated. The first 79 patients were 
implanted with loose seeds (seedSelect, Nucletron) and the next 68 
patients with stranded seeds (IsoSeed, Bebig). Loose seeds (LS) were 
delivered automatically with the seedSelectron system, while 
stranded seeds (SS) were placed into the prostate manually. For 
treatment planning the SPOT PRO 3.1 (Nucletron) software was used 
for all patients. The number and positions of seeds were calculated 
with an inverse dose optimization algorithm (IPSA) in the pre-implant 
plan. Then, the seeds were implanted under transrectal ultrasound 
guidance, and their real positions were updated in live planning. The 
prescribed dose was 145 Gy. Dose-volume histograms were calculated 
and volumetric parameters were used to evaluate the plans. V100 (%), 
DHI, D90 (Gy) and COIN were determined for the prostate, while Dmax 
(%), D0.1cm3 (%), D10 (%), D30 (%) for the urethra, and Dmax (%), 
D0.1cm3 (Gy), D2cm3 (Gy), D10 (%) for the rectum. Means and standard 
deviations were calculated and compared for both intervention 
groups. 
Results: On average, 54 and 47 seeds were implanted in the prostate 
with individual median seed activities of 0.49 and 0.56 mCi for LS and 
SS technique, respectively. The median needle number was 15 and 17, 
correspondingly. The mean prostate volumes were practically 
identical (33.4 vs. 33.9 cm3). The dose coverage was similar (V100: 
96% vs. 97%, D90: 167 Gy vs.169 Gy) in the two groups, and the dose 
homogeneity was identical (DHI: 0.39). The conformity of dose 
distributions was better for LS (COIN: 0.70 vs. 0.65). Regarding the 
dose to urethra all dosimetric parameters were significantly lower 
(p<0.05) for LS (Dmax: 138% vs. 154%, D0.1cm3: 126 vs. 140 %, D10: 125 
vs. 136 % and D30: 119 vs. 128 %). The rectum received less dose with 
the LS technique (Dmax: 101% vs. 112 %, D2cm3: 82 Gy vs. 97 Gy, 
D0.1cm3 :127 vs. 143 Gy, and D10: 75% vs. 86%) (p<0.05 for all). 
Conclusions: In permanent prostate seed brachytherapy the dose to 
urethra and rectum is less with LS technique compared to SS 
technique in the intraoperative plans. Moreover, the conformity of 
dose distributions is also better with LS along with the same 
homogeneity of dose distributions. Probably the more flexible loading 
pattern for LS technique results in the more favourable dose 
distributions.  
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Purpose/Objective: A survey of high dose rate (HDR) brachytherapy 
quality control (QC) procedures undertaken at radiotherapy centres in 
the United Kingdom (UK) is reported [1]. Published recommendations 
and guidance for HDR QC are also reviewed and compared to current 
UK practice. Recent changes in clinical brachytherapy techniques and 
the impact on required QC is discussed. Modern methods to determine 
optimum quality checking processes are indicated. This work is 
conducted in the context of the recent 'point/counterpoint' debate in 
Medical Physics that 'QA procedures in radiation therapy are outdated 
and negatively impact the reduction of errors' [2] and a review of the 
dosimetric accuracy in HDR [3]. 
[1] AL Palmer, M Bidmead, A Nisbet. J Contemp Brachy 2013 (in press) 
[2] HI Amols, EE Klein. Med Phys 2011; 38: 5835-5837  
[3] A Palmer, D Bradley, A Nisbet. J Contemp Brachy 2012; 4: 81-91  
Materials and Methods: All UK radiotherapy centres were asked to 
participate in a survey of their approach and practice for HDR 
brachytherapy QC. This included guidance used, frequencies and 
tolerance values for individual QC tests. A comprehensive evaluation 
of responses was conducted detailing popularity of tests, and the 
average and range values of testing and tolerance. A literature search 
was conducted on general guidance, specific QC techniques in both 
brachytherapy and teletherapy, and on risk-based systems for quality 
assurance.  
Results: Survey data was acquired from 31 UK radiotherapy centres 
and statistical analysis of responses performed. 45 possible individual 
QC tests were identified. There was general agreement on 
measurement frequency and tolerance for key QC tests, e.g. 
measurement of source position in a straight catheter, checked daily 
and with a 1.0mm tolerance in most centres. There was disagreement 
on a number of tests, e.g. the need for regular x-ray imaging of 
applicators. There was absence of tests that may be deemed 
necessary for modern brachytherapy practice, e.g. confirmation of 
planned and delivered dose distributions. There is likely a need to 
move from a device-centred to a system-centred approach, using risk-
based assessment methods to determine required QC testing, with 
emphasis on clinical processes rather than simple device operation. 
Table 1 provides sample key results from the work. 
 Conclusions: The only contemporary benchmark survey of HDR QC 
practice has been undertaken. The outcome of this work is a review of 
current practice against available recommendations, relevant recent 
changes in clinical brachytherapy techniques, and the use of modern 
quality process assessments. Recommendations for appropriate, 
optimised QC for HDR brachytherapy are made. 
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